Assessing benefit and risk in the prevention of prostate cancer: The prostate cancer prevention trial revisited

Journal of Clinical Oncology

Volumn 23, Issue 30, 2005, Pages 7460-7466

  Klein, Eric A ^a   Tangen, Catherine M ^a   Goodman, Phyllis J ^a   Lippman, Scott M ^a   Thompson, Ian M ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO; ENZYME INHIBITOR;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; UNITED STATES; ADENOCARCINOMA; CANCER STAGING; NEEDLE BIOPSY; PROGNOSIS; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; RISK; TREATMENT OUTCOME;

ADENOCARCINOMA; BIOPSY, NEEDLE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 32944472917     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.159     Document Type: Article

References (26)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 17: 215-224, 2003
3. Civantos F, Soloway MS, Pinto JE: Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 14:22-31, 1996
4. Bostwick DG, Qian J, Civantos F, et al: Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2:228-235, 2004
5. Rubin MA, Kantoff PW: Effect of finasteride on risk of prostate cancer: How little we really know. J Cell Biochem 91:478-482, 2004
6. Marks LS, Partin AW, Dorey FJ, et al: Long-term effects of finasteride on prostate tissue composition. Urology 53:574-580, 1999
7. Uzzo RG, Wei JT, Waldbaum RS, et al: The influence of prostate size on cancer detection. Urology 46:831-836, 1995
8. Jhaveri FM, Klein EA, Kupelian PA, et al: Declining rates of extracapsular extension in radical prostatectomy: Evidence for continued stage migration. J Clin Oncol 17:3167-3172, 1999
9. Clark PE, Levin HS, Kupelian PA, et al: Intermediate-term outcome with radical prostatectomy for localized prostate cancer: The Cleveland Clinic Experience. Prostate J 3:118-125, 2001
10. Eastham JA, Scardino PT: Radical prostatectomy for clinical stage T1 and T2 prostate cancer, in NJ Vogelzang, PT Scardino, WU Shipley et al (eds): Comprehensive Textbook of Genitourinary Oncology (ed 2). Philadelphia, PA, Lippincott Williams & Wilkins, 1999, pp 722-738
11. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 152:1831-1836, 1994
12. Catalona WJ, Ramos CG, Carvalhal GF: Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 49:282-296, 1999
13. Kupelian PA, Elshaikh M, Reddy CA, et al: Comparison of the efficacy of local therapies for localized prostate cancer in the PSA era: A large single institution experience with radical prostatectomy and external beam radiotherapy. J Clin Oncol 20:3376-3385, 2002
14. Jhaveri FM, Zippe CD, Klein EA, et al: Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10 year results. Urology 54:884-890, 1999
15. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
16. Stanford JL, Feng Z, Hamilton AS, et al: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 283:354-360, 2000
17. Potosky AL, Legler J, Albertsen PC, et al: Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92:1582-1592, 2000
18. Mehta SS, Lubeck DP, Pasta DJ, et al: Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: Results from CaPSURE. J Urol 170:1931-1933, 2003
19. Thompson IM, Tangen C, Goodman P: The Prostate Cancer Prevention Trial: Design, status, and promise. World J Urol 21:28-30, 2003
20. Harlan SR, Cooperberg MR, Elkin EP, et al: Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer. Results from CaPSURE. J Urol 170:1804-1807, 2003
21. Thompson I, Klein EA, Lippman SM, et al: Prevention of prostate cancer with finasteride: A U.S./European perspective. Eur Urol 44:650-655, 2003
22. Walsh PC: Editorial comment. J Urol 171: 506-507, 2004
23. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350:2239-2246, 2004
24. Punglia RS, D'Amico AV, Catalona WJ, et al: Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349:335-342, 2003
25. Wolmark N, Dunn BK: The role of tamoxifen in breast cancer prevention: Issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann N Y Acad Sci 949:99-108, 2001
26. Randal J: The end of an era? Study reveals harms of hormone replacement therapy. J Natl Cancer Inst 94:1116-1118, 2002